Aktie A400D1 TITAN PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Titan Pharmaceuticals, Inc.

Aktien

A400D1

US8883147055

TTNP

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 26.04.2024 		% 5 Tage % 1. Jan.
7,09 USD +1,72 % Intraday Chart für Titan Pharmaceuticals, Inc. -3,14 % -14,06 %
01.04. Titan Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
26.01. Titan Pharmaceuticals erfüllt wieder die Nasdaq-Listing-Regel MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Titan Pharmaceuticals : Non-Reliance on Previously Issued Financial Report - Form 8-K
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Titan Pharmaceuticals : Private Placement - Form 8-K
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - December 28, 2023
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
Titan Pharmaceuticals: Q3 Earnings Snapshot
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Titan Pharmaceuticals, Inc. Announces Board Changes
Titan Pharmaceuticals Appoints New Chairman of the Board
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
Titan Pharmaceuticals, Inc. Announces Board Resignations
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd
TITAN PHARMACEUTICALS : UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION - Form 8-K
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..
Titan Pharmaceuticals: Q2 Earnings Snapshot
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A400D1 Aktie
  4. Nachrichten Titan Pharmaceuticals, Inc.
  5. Andere Sprachen